OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.
Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.
Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.
Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.
Archiving: full-text archived in CLOCKSS.
Rapid publication: manuscripts are undertaken in 8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).
Ischemic Heart Disease in the Elderly
Submission Deadline: May 30, 2021 (Open) Submit Now
Clara Bonanad, MD, PhD
Servicio de Cardiología, Hospital Clínico Universitario, INCLIVA, Universitat de Valencia, Valencia, Spain
Research Interests: Myocardial infarction; echocardiography; pacemakers; cardiac imaging; diabetes; cardiovascular; heart failure; cardiology; coronary artery disease; acute heart failure; acute coronary syndrome
About this Topic
Ischemic heart disease in the elderly patient has a series of peculiarities: increased morbidity and mortality, underdiagnosis, under-treatment, procedural complications, pharmacological side-effects, etc . However, specific recommendations in this context are limited to the use of drug-eluting stents (IA), radial access (IB), and assessment of frailty, comorbidities, and side effects (IC) [2, 3]. In other words, there is a need to find specific evidence that justifies further research in this field.
Urgent reperfusion is the established standard of care in ST segment elevation myocardial infarction (STEMI) even in the elderly . However, in the acute coronary syndrome (ACS) without ST segment elevation setting there is a lack of solid evidence on whether an invasive or a conservative strategy is indicated. A recent meta-analysis found that those ≥65 years treated invasively have a lower rate of subsequent revascularization but without differences in mortality, infarction or stroke . Moreover, randomized trials addressing this issue yield controversial results . Influence of comorbidities and frailty may be crucial in determining the appropriate strategy.
To prevent robots and page crawlers from submitting fraudulent forms, complete verification to prove that you are a human.